NCT03868020View on ClinicalTrials.gov

Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 24, 2019

Primary Completion Date

March 22, 2024

Study Completion Date

March 22, 2024

Conditions
Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Squamous Cell Carcinoma in Cervical Lymph Node
Interventions
PROCEDURE

Computed Tomography

Undergo PET/CT

RADIATION

Fluciclovine F18

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03868020 - Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease | Biotech Hunter | Biotech Hunter